drugset / Trial / NCT06062602

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

NCT06062602

Phase 0 Completed 15 enrolled Presage Biosciences Takeda · collab
NaSingle-groupOpen-labelBasic science

Summary

This is a multi-center, open-label Phase 0 substudy designed to study the localized pharmacodynamics (PD) of TAK-676 alone or in combination with Carboplatin, 5-FU, or Paclitaxel within the tumor microenvironment (TME) when administered intratumorally in microdose quantities via the CIVO device in patients diagnosed with Head and Neck Squamous Cell Carcinoma presenting with a surface accessible solid tumor for which there is a scheduled surgical intervention. This substudy is a cohort of the PBI-MST-01 Master Protocol.

Timeline

Start
2021-07-26
Primary completion
2022-11-15
Completion
2022-11-15

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule Other
Subject Dazostinag Small molecule Other
Subject Paclitaxel Small molecule Other
Subject fluorouracil Small molecule Other